Table 1.
Descriptive statistics for the measures of estrogen receptor expression by follow-up outcome
| Overall |
Follow-up outcome |
||||
|---|---|---|---|---|---|
| Died from breast cancer | Died from other causes | Alive at the end of follow-up | P F-test | ||
|
Overall |
n = 1,204 |
n = 272 |
n = 63 |
n = 869 |
|
| ER-positivea (%) |
58.0 |
42.5b |
67.0b |
61.8b |
|
| Among women with ER-positivea tumor |
|
|
|
|
|
| % of tumor cell nuclei positively stained for ER |
64.7 (25.5) |
62.2 (27.0) |
65.6 (24.5) |
65.1 (25.2) |
0.53 |
| ER H-scorec |
100.8 (53.0) |
93.0 (52.9) |
104.5 (54.6) |
102.2 (52.9) |
0.22 |
| ER/PR/HER2 scored |
–64.8 (40.6) |
–49.9 (43.5) |
–65.7 (34.7) |
–67.9 (39.8) |
<0.0001 |
|
White women |
n = 681 |
n = 131 |
n = 24 |
n = 526 |
|
| ER-positivea (%) |
62.5b |
47.2b |
78.6b |
65.8b |
|
| Among women with ER-positivea tumor |
|
|
|
|
|
| % of tumor cell nuclei positively stained for ER |
64.6 (25.9) |
58.0 (27.4) |
74.4 (18.1) |
65.2 (25.7) |
0.03 |
| ER H-scorec |
100.7 (53.2) |
82.3 (48.8) |
122.1 (44.9) |
102.8 (53.7) |
0.004 |
| ER/PR/HER2 scored |
–67.6 (39.7) |
–46.1 (44.7) |
–78.8 (26.3) |
–70.8 (38.2) |
<0.0001 |
|
Black women |
n = 523 |
n = 141 |
n = 39 |
n = 343 |
|
| ER-positivea (%) |
51.3b |
38.0b |
60.0b |
55.8b |
|
| Among women with ER-positivea tumor |
|
|
|
|
|
| % of tumor cell nuclei positively stained for ER |
64.8 (24.9) |
67.2 (25.9) |
58.3 (26.9) |
65.0 (24.3) |
0.35 |
| ER H-scorec |
100.9 (52.8) |
105.5 (55.2) |
90.0 (58.4) |
101.0 (51.5) |
0.50 |
| ER/PR/HER2 scored | –60.3 (41.8) | –54.3 (42.1) | –54.8 (37.4) | –62.7 (42.1) | 0.35 |
Data presented as mean (standard deviation). ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
aER-positive, ≥1% positively stained tumor cell nuclei.
bThe distribution of age at diagnosis in each subgroup was adjusted according to the distribution of age at diagnosis among the 1,204 participants (35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, or 60 to 64 years).
cER Histo (H)-score = (% of positively stained tumor cell nuclei at weak intensity category × 1) + (% of positively stained tumor cell nuclei at intermediate intensity category × 2) + (% of positively stained tumor cell nuclei at strong intensity category × 3).
dER/PR/HER2 score = 94.7 × (–0.100 ER10 – 0.079 PR10 + 0.586 HER2).